Published in Medicine and Law Weekly, September 1st, 2006
Claims in this patent cover a broad series of innovative steps that together compose a scaleable process for manufacturing alphavirus replicon particle vaccines (alphavaccines).
The company's alphavaccine platform allows the incorporation of a wide range of antigens to produce vaccines targeting infectious disease, cancer and biodefense threats. AlphaVax has counterparts to this patent pending or issued in 10 major countries and regions throughout the world.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.